Core Team & Global Advisor Network
A team grounded in health economics and HTA methodology, connected to leading global health-economics & policy experts — bringing evidence-based decision-making to every overseas engagement.
Founding Team
Two co-founders lead the group's two tracks — overseas market-access services and digital health-economics products.
Dr. Yang
Co-founder · Head of Overseas Business · Chairman
PhD in Public Health from The University of Hong Kong (pharmacoeconomics & HTA), BSc in Pharmaceutical Science from Ocean University of China. Former senior technician at the Guangzhou Institutes of Biomedicine and Health, CAS; certificates from Harvard (age-friendly society) and Peking University.
Methodology: Cost-effectiveness analysis (CEA), budget-impact analysis (BIA), Markov modelling and other core health-economics methods; deep understanding of the government perspective in evidence-based decisions.
Track record: led overseas order negotiations, executed government tendering processes, and advanced projects to reimbursement-negotiation stage.
Academic & credentials: 4 projects led/participated, ~¥2M cumulative funding, 10+ papers, an invention patent (gouty arthritis diagnostic kit), plus Harvard and Peking University certificates.
Ms. Yang
Co-founder · Head of Digital Product Lines (Qiyang No.1 / No.2 / No.3)
Driven by health economics and evidence-based medicine, closing the "academic research → product" loop. Led health-economic modelling to CHEERS 2022 standards; research has informed regional health-service reimbursement pricing policy; background in health-economic research and international academic exchange.
Qiyang No.1 · C-end chronic-disease management: consumer health management focused on chronic conditions.
Qiyang No.2 · Medical-economics SaaS: decision-support platform for hospitals, pharma and payers with multi-model health-economic analysis.
Qiyang No.3 · Global HTA platform: health technology assessment serving multi-country access & value assessment.
Domestic Core Team
A multidisciplinary backbone across regulatory affairs, commercial finance, operations and R&D/medical affairs.
Ms. Yang · Regulatory Affairs Expert
Licensed Pharmacist (MSc) · RAPS member (US)
- 10+ years in drug registration across China, US, EU, Southeast Asia and Latin America (IND and NDA/BLA).
- Deep experience with regulatory requirements and launch strategies for new chemicals, generics, traditional/plant medicines and biosimilars.
- Led/contributed to 50+ submission projects.
Dr. Jiang · Commercial & Financing
BSc (Southwest University of Science and Technology) · EMBA (Zhejiang University)
- 10+ years across investment, e-commerce and internet, leading commercial channels.
- Supports the CEO on financing; strong commercial instincts.
Mr. Li · Operations Director
BSc in Public Health (Sichuan University)
- Deep involvement in operations, maintenance and R&D; leads project R&D for the Suzhou company.
- Contributes to Saudi pharmacoeconomics assessments, Middle East Bridge projects and health/wellbeing research.
Dr. Ji · R&D Technical Director
Medical Affairs Expert · Physician · PhD (Peking University Health Science Center)
- 10+ years in R&D and pharma registration covering new drugs, generics, imported products and overseas expansion.
- Led 50+ IND/NDA/ANDA submissions with >90% approval rate; handled 100+ deficiency-response issues.
- Specializes in China/US/Australia filings and OTC conversion applications.
Overseas Expert Advisor Network
Ongoing collaboration with leading global health-economics & health-policy experts for methodology, international standards and multi-country access.
🏥 Health Technology Assessment (HTA) Advisor · Prof. MJ
HTA methodology expert with a Harvard Medical School / Massachusetts General Hospital (MGH) background; advisor to WHO and the World Bank on health-economic evaluation; reviews Qiyang's pharmacoeconomic models and international HTA document standards.
🇪🇺 European Health Policy Advisor · Prof. Elias
European health-policy expert with a London School of Economics (LSE) background; former senior advisor to the European Commission; supports healthcare-reform policy interpretation, pricing-strategy design and payer negotiation.
🌏 Asian Government Policy Network
Government health-policy expert resources across Hong Kong, Japan and Singapore, plus Thailand HITAP and GCC policy-access networks for on-the-ground access and negotiation support.
Practice-integrated: The advisor network is deeply involved in Qiyang's project review and strategy — from pharmacoeconomic model review and international HTA standardization to healthcare-reform policy interpretation and payer negotiation — delivering "international standard × local execution" on every project.
Want to go overseas with a team like this?
Tell us about your product, and Qiyang's team and global advisors will map your access path.
Contact us